Off-the-Shelf CAR-T cells take on tough leukemia
NCT ID NCT07432100
First seen Mar 29, 2026 · Last updated Apr 24, 2026 · Updated 5 times
Summary
This early-stage study tests a new type of immunotherapy called universal CLL1 CAR-T cells for people with acute myeloid leukemia (AML) that has come back or not responded to standard treatments. The therapy uses donor immune cells engineered to target and kill leukemia cells, aiming to achieve remission. The study will enroll 20 adults to evaluate safety, effectiveness, and how long the treatment works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.